Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

New endocrine agents for prevention of breast cancer

MBCC 12

16 - 18 Jun 2010

Published: 3 Sep 2010

Views: 7657

Rating:

Save

Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK

Prof Jack Cuzick - Wolfson Institute of Preventive Medicine, London, UK, speaking at the 12th Milan Breast Cancer Conference, June 2010: New endocrine agents for prevention of breast cancer. Download the accompanying slides here.

Related Videos

Tackling breast cancer screening in conservative communities

Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America

Tackling breast cancer screening in conservative communities ( Dr Ru'a Rimawi - Dana-Farber Cancer Institute, Boston, United States of America )

Post-diagnosis diet, nutrition and cancer prognosis

Dr Doris Chan - Imperial College London, London, UK

Post-diagnosis diet, nutrition and cancer prognosis ( Dr Doris Chan - Imperial College London, London, UK )

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies ( Dr Marc Machaalani - Dana-Farber Cancer Institute, Boston, USA )

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC ( Dr Oleg Gluz - Evangeliches Krankenhaus Bethesda Klinik, Mönchengladbach, Germany )

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy

Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy ( Prof Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Dr Dejan Juric - Massachusetts General Hospital, Boston, USA

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer ( Dr Dejan Juric - Massachusetts General Hospital, Boston, USA )

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer ( Dr Sitna Mwanzi - Kenyatta National Hospital, Nairobi, Kenya )

More from ecancer